Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
NCT ID: NCT00137371
Last Updated: 2007-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
480 participants
INTERVENTIONAL
2005-08-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PVC (daily for 21 days, 7 days off)
PVC (twice weekly)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.
Exclusion Criteria
45 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: PRINCIPAL_INVESTIGATOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Encinitas, California, United States
San Diego, California, United States
Torrance, California, United States
Aurora, Colorado, United States
Brooksville, Florida, United States
Miami, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Metairie, Louisiana, United States
Troy, Michigan, United States
St Louis, Missouri, United States
Omaha, Nebraska, United States
New Brunswick, New Jersey, United States
Chapel Hill, North Carolina, United States
Winston-Salem, North Carolina, United States
Oklahoma City, Oklahoma, United States
Danville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Carrollton, Texas, United States
Carrollton, Texas, United States
Colleyville, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Plano, Texas, United States
Charlottesville, Virginia, United States
Norfolk, Virginia, United States
Calgary, Alberta, Canada
Coquitlam, British Columbia, Canada
Langley, British Columbia, Canada
Winnipeg, Manitoba, Canada
Winnipeg, Manitoba, Canada
Kingston, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Montréal, Quebec, Canada
Montréal, Quebec, Canada
Montreal, Quebec, Canada
Pointe-Claire, Quebec, Canada
Québec, Quebec, Canada
Shawinigan, Quebec, Canada
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0713S5-413
Identifier Type: -
Identifier Source: org_study_id